Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INDV
STRONG BUYFLAGIndivior Pharmaceuticals, Inc. · Healthcare · United States · $4.8B · Avg Vol: $70M/d
Indivior has value at V41, below the calibrated floor, so the strong M84 momentum and plus 4.4% revision cannot carry it, and insiders sold 0.06%. Opioid addiction treatment with a complex litigation and competitive history.
COMPANY DESCRIPTION
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company focused on developing and commercializing treatments for opioid use disorder (OUD) and other serious mental health conditions. The company possesses a leading market position in the treatment of opioid dependence, particularly with its flagship product Sublocade, benefiting from intellectual property protection and established clinical efficacy. It is a dedicated pharmaceutical company addressing the opioid crisis with innovative long-acting injectable treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 901.0M | 1.1B | 1.2B | 1.2B | 11.2% | 1.3B | 1.3B | 1.3B | 2.9% |
| EPS | -0.38 | 0.01 | -0.36 | 1.68 | 1196.1% | 1.88 | 2.59 | 2.80 | 29.1% |
| Shares | 136.5M | 136.5M | 124.9M | 125.0M | -8.4% | 118.2M | — | — | — |
| Debt | 277.0M | 283.0M | 375.0M | 351.0M | 8.2% | 509.0M | — | — | — |
| Equity | 51.0M | -192.0M | -337.0M | -99.0M | — | — | — | — | — |
| Op CF | -4.0M | -300.0M | 36.0M | -27.0M | — | -111.0M | — | — | — |
| Inv CF | -222.0M | -95.0M | 69.0M | -66.0M | — | — | — | — | — |
| Fin CF | -101.0M | -64.0M | -102.0M | -30.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INDV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INDV | Indivior Pharmaceuticals, Inc.(you) | $4.8B | 91 | STRONG BUY |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.7B | 87 | STRONG BUY |
| LNTH | Lantheus Holdings, Inc. | $6.8B | 93 | STRONG BUY |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.4B | 88 | STRONG BUY |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 93 | STRONG BUY |
| PBH | Prestige Consumer Healthcare Inc. | $2.4B | 82 | STRONG BUY |
| ANIP | ANI Pharmaceuticals, Inc. | $1.8B | 97 | STRONG BUY |
| TRLV | Trulieve Cannabis Corp. | $1.6B | 87 | STRONG BUY |
| NBIX | Neurocrine Biosciences, Inc. | $17.7B | 91 | STRONG BUY |
| VIA.DE | Viatris Inc. | $19.0B | 90 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%